Compounds > ro 11-2933
Page last updated: 2024-09-03

ro 11-2933 and verapamil

ro 11-2933 has been researched along with verapamil in 7 studies

Compound Research Comparison

Studies
(ro 11-2933)		Trials
(ro 11-2933)		Recent Studies (post-2010)
(ro 11-2933)		Studies
(verapamil)		Trials
(verapamil)		Recent Studies (post-2010) (verapamil)
130017,6211,5272,067

Protein Interaction Comparison

ProteinTaxonomyro 11-2933 (IC50)verapamil (IC50)
Solute carrier family 22 member 1 Homo sapiens (human)6.8
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)0.2
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.297
ATP-dependent translocase ABCB1Mus musculus (house mouse)2
ATP-dependent translocase ABCB1Homo sapiens (human)2.2346
Cytochrome P450 3A4Homo sapiens (human)3.8008
Alpha-2A adrenergic receptorHomo sapiens (human)0.579
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)3.02
ATP-dependent translocase ABCB1Mus musculus (house mouse)10
Catechol O-methyltransferaseHomo sapiens (human)0.2
Potassium voltage-gated channel subfamily A member 3Homo sapiens (human)8
Histamine H2 receptorHomo sapiens (human)2.59
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.442
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.297
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)3.02
Sodium-dependent serotonin transporterHomo sapiens (human)0.24
Multidrug resistance-associated protein 1 Homo sapiens (human)5.598
D(3) dopamine receptorHomo sapiens (human)0.186
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.165
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)6.8
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)0.2
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.3945
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)0.2
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)0.175
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.1934

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19902 (28.57)18.7374
1990's5 (71.43)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bankusli, I; Rustum, YM; Yin, MB1
Bankusli, I; Mayhew, E; Radel, S; Rustum, YM1
Bines, SD; Chong, AS; Coon, JS; Gebel, HM; Markham, PN1
Bicknell, SR; Hamilton, T; Kaye, SB; Morrison, JG; Plumb, JA; Setanoians, A; Wishart, GC1
Kyle, DE; Milhous, WK; Rossan, RN1
Alaoui-Jamali, MA; Batist, G; Centurioni, MG; Lehnert, S; Rustum, YM; Schecter, RL1
Abderrabi, M; Marchal, S; Merlin, JL1

Other Studies

7 other study(ies) available for ro 11-2933 and verapamil

ArticleYear
Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice.
    Cancer research, 1989, Sep-01, Volume: 49, Issue:17

    Topics: Animals; Calcium Channel Blockers; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Resistance; Female; Mice; Mice, Inbred DBA; Propylamines; Verapamil

1989
The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo.
    Cancer chemotherapy and pharmacology, 1988, Volume: 21, Issue:1

    Topics: Animals; Calcium Channel Blockers; Doxorubicin; Drug Resistance; Drug Synergism; Female; Glycoproteins; Leukemia P388; Leukemia, Experimental; Mice; Mice, Inbred DBA; Propylamines; Tumor Cells, Cultured; Verapamil

1988
Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells.
    Cancer immunology, immunotherapy : CII, 1993, Volume: 36, Issue:2

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Drug Resistance; Humans; Killer Cells, Natural; Membrane Glycoproteins; Propylamines; Rhodamine 123; Rhodamines; Verapamil

1993
Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft.
    Biochemical pharmacology, 1994, Jan-20, Volume: 47, Issue:2

    Topics: Animals; Calcium Channel Blockers; Doxorubicin; Drug Resistance; Drug Synergism; Epirubicin; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Propylamines; Quinidine; Tumor Cells, Cultured; Verapamil

1994
Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys.
    The American journal of tropical medicine and hygiene, 1993, Volume: 48, Issue:1

    Topics: Animals; Aotus trivirgatus; Calcium Channel Blockers; Chloroquine; Chlorpromazine; Cyproheptadine; Disease Models, Animal; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Ketotifen; Malaria, Falciparum; Plasmodium falciparum; Prochlorperazine; Propylamines; Verapamil

1993
In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933.
    The Journal of pharmacology and experimental therapeutics, 1993, Volume: 264, Issue:3

    Topics: Animals; Calcium Channel Blockers; Cell Division; DNA Damage; Doxorubicin; Drug Resistance; Female; Mammary Neoplasms, Experimental; Propylamines; Rats; Rats, Inbred F344; Tumor Cells, Cultured; Verapamil

1993
Comparative in vitro evaluation of dithiane analogs of tiapamil, Ro 11-2933, Ro 44-5911 and Ro 44-5912 as multidrug resistance modulators.
    Anti-cancer drugs, 1996, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Breast Neoplasms; Calcium Channel Blockers; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Leukemia, Experimental; Propylamines; Tumor Cells, Cultured; Verapamil

1996